source
- BioCryst to rely on external partnerships after ending internal discovery programsBioCryst Pharmaceuticals CEO Charlie Gayer told Fierce that the company remains committed to science and research even as it shuts down its internal discovery efforts. Earlier this year the firm’s…
- FDA grants accelerated approval to Bristol Myers' iberdomide for relapsed or refractory multiple myelomaThe U.S. Food and Drug Administration has issued an accelerated approval for iberdomide, a small-molecule therapy developed by Bristol Myers Squibb. The approval targets patients with multiple mye…